Author

Rex C. Bentley

Duke UniversityORCID 0000-0002-4947-9150Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:benchmark study· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Ara JoiD· 2 shared Corinne Mary LinardiciD· 2 shared Elizabeth A. MendesiD· 2 shared Aanandi MunshiiD· 1 shared Alexander R. KovachiD· 1 shared Allen Thayakumar BasanthakumariD· 1 shared Archana SinghiD· 1 shared Assil FahsiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ara JoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma

Susu Zhang, Kathleen L. Engel, Assil Fahs, Ara Jo, Clare F. Malone, Kenneth N. Ross, Marissa A. Just, Brian Guedes, Diyana Granum, Kristianne Michelle Oristian, Alexander R. Kovach, Gabriela Alexe, Giulia DiGiovanni, Leen Barbar, Rex C. Bentley, , Kimberly Stegmaier

This study identifies CDK8 inhibition as a therapeutic strategy for alveolar rhabdomyosarcoma by inducing myogenic differentiation and impairing tumor growth through a mechanism involving the Mediator kinase module, SAGA complex, and SIX4.

Cancer Discovery · Jul 14, 2026Peer-reviewedCancer Biology

RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma

Elizabeth A. Mendes, Aanandi Munshi, Archana Singh, Maisie D. Evans, Hsien-Chao Chou, Yong Yean Kim, Young Song, Ara Jo, Daniel Lee, Jaida Ciampi, Audrey L. Chambers, Samantha Weitzel, Michael D. Deel, Rex C. Bentley, Javed Khan, , Corinne Mary Linardic

This study identifies RUNX2 as a druggable target in fusion-positive rhabdomyosarcoma, showing its inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and reduces tumor growth.

bioRxiv · Jul 21, 2025 · PreprintCancer Biology